Stay updated on Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial
Sign up to get notified when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.

Latest updates to the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page
- Check3 days agoChange DetectedThe page now indicates recruitment has closed and introduces new user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study); the Intervention/Treatment heading formatting and the site version have been updated from v3.5.5 to v3.6.0.SummaryDifference0.2%

- Check10 days agoChange DetectedA new revision tag v3.5.5 was added and the previous v3.5.4 tag was removed. This indicates a minor update to the page's version metadata.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedThe page shows Revision: v3.5.4, replacing the previous v3.5.3, indicating a new platform release or patch rather than a change to the study data.SummaryDifference0.0%

- Check54 days agoChange DetectedThe page revision label has been updated from v3.5.2 to v3.5.3. This reflects a site/version metadata refresh rather than a change to the clinical study information presented.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check83 days agoChange DetectedAdded new trial sites: Wrocław, Poland (51-685) and Lviv, Ukraine (79029), and added the collaborator 'Neurofocus LLC'. Removed outdated site entries for Wroclaw (51-685), Lviv in Chernihiv Governorate (79007), and the MNE Lviv Territorial Medical Association Clinical Hospital for Palliative Care.SummaryDifference0.3%

Stay in the know with updates to Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.